Wall Street Zen Upgrades Bicycle Therapeutics (NASDAQ:BCYC) to Sell

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages also recently issued reports on BCYC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Needham & Company LLC decreased their price target on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Citigroup reissued a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, April 30th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $13.86.

Bicycle Therapeutics Price Performance

Shares of NASDAQ:BCYC opened at $3.90 on Friday. The stock has a market capitalization of $272.96 million, a PE ratio of -1.43 and a beta of 1.55. The firm’s 50 day moving average price is $4.10 and its 200-day moving average price is $4.72. Bicycle Therapeutics has a twelve month low of $3.74 and a twelve month high of $9.16.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). The business had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. Analysts expect that Bicycle Therapeutics will post -2.23 earnings per share for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 5,905 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total transaction of $25,214.35. Following the transaction, the chief executive officer directly owned 605,408 shares in the company, valued at approximately $2,585,092.16. This represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 9,977 shares of company stock valued at $42,702 in the last ninety days. 22.00% of the stock is owned by company insiders.

Institutional Trading of Bicycle Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC increased its stake in Bicycle Therapeutics by 8.7% in the 4th quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock worth $22,911,000 after buying an additional 258,000 shares during the period. Renaissance Technologies LLC boosted its position in Bicycle Therapeutics by 72.8% in the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock valued at $4,544,000 after buying an additional 412,700 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Bicycle Therapeutics during the fourth quarter valued at approximately $954,000. Flax Pond Capital LLC purchased a new stake in shares of Bicycle Therapeutics in the fourth quarter valued at approximately $1,229,000. Finally, Pinnacle Wealth Management Advisory Group LLC bought a new position in Bicycle Therapeutics in the fourth quarter worth approximately $71,000. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.